Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DINAMO pediatric type 2 diabetes trial of empagliflozin and linagliptin
2016-000669-21Phase 3Terminated
- Sponsor
- Unilfarma
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin, Linagliptin and Placebo (3 arms). Primary endpoint: Change from baseline in HbA1c. Started Jan 2018; status: terminated.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000669-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000669-21.